Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...

The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday.

The current public-health risk is low, but the CDC is watching the situation carefully and working with states to monitor ...

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.

The biotech company said it anticipates between $1.5 billion and $2.5 billion in revenue this year, below Wall Street ...

Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half ...

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...

The biotech group struggled as a whole in 2024, but analysts say the innovation that has always supported the biotech ...

Moderna is still generating decent sales from its COVID-19 vaccine. The biotech has won important clinical and regulatory approvals this year. Moderna's portfolio should look much stronger in a ...

Moderna's stock plummeted to an almost five-year low after the biotech company cut its revenue outlook for this year and said that sales for last year will come in at the lower end of its guidance.

In the third quarter, Moderna reported $1.9 billion in revenue, roughly flat compared to the year-ago period. On the bottom line, the biotech reported net earnings per share of $0.03 compared to a ...